S100A7 and breast neoplasm: To determine if the S100A7/cPLA2 signaling axis could be exploited as a potential therapeutic target against metastatic breast cancer, we analyzed the clinical utility of cPLA2 inhibitor against breast tumor growth and metastasis using the Hu-PDX mouse model.